The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA ...
Moderna (NASDAQ:MRNA) announced Friday that the U.S. Food and Drug Administration (FDA) has pushed back its timeline to complete the review of its marketing application for mRNA-1345, a messenger ...
Moderna (NASDAQ:MRNA) shares are down just over 1% in early Friday trading after the company said the FDA has informed it that it will not be able to meet the May 12 PDUFA for their RSVvaccine ...
Some results have been hidden because they may be inaccessible to you